This inventor holds 1 USPTO granted patent. Top assignee: Ontogen Corporation. Active years: 2000.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2000
Title: Kevin Michael Short: Innovator in Fructose-1,6-Bisphosphatase Inhibition
Introduction
Kevin Michael Short is a notable inventor based in Vista, California. He has made significant contributions to the field of biochemistry, particularly in the development of inhibitors for fructose-1,6-bisphosphatase (FBPase). His innovative work has implications for various metabolic disorders.
Latest Patents
Kevin holds a patent for "Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)." This patent includes compounds of formula A, where R¹ is aralkyl or cycloalkyl, and R² is cycloalkylmethyl, alkyl, or aralkyl. He has 1 patent to his name, showcasing his focused research in this specialized area.
Career Highlights
Kevin is currently employed at Ontogen Corporation, where he continues to explore innovative solutions in biochemistry. His work at Ontogen has allowed him to collaborate with other talented professionals in the field.
Collaborations
Some of Kevin's coworkers include Adnan M Mjalli and James Christopher Mason. Their collective expertise contributes to the advancement of research and development at Ontogen Corporation.
Conclusion
Kevin Michael Short is a dedicated inventor whose work in fructose-1,6-bisphosphatase inhibition is paving the way for future innovations in metabolic research. His contributions are valuable to the scientific community and hold promise for therapeutic advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile